Kostas Biliouris
Stock Analyst at BMO Capital
(1.26)
# 3,676
Out of 5,032 analysts
63
Total ratings
38.78%
Success rate
-11.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $22.51 | +122.12% | 9 | Sep 22, 2025 | |
| TRML Tourmaline Bio | Downgrades: Market Perform | $35 → $48 | $47.90 | +0.21% | 1 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $481.67 | -2.42% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $73.09 | -4.23% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $2.45 | +63.27% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.71 | +115.63% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $47.89 | +50.34% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $16.38 | +205.25% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $6.50 | +284.62% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $24.75 | +102.02% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.90 | +392.75% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $23.02 | +52.04% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $3.05 | +457.38% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $9.84 | +306.50% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $31.96 | +181.60% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $42.15 | +184.70% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $25.98 | +119.40% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $54.92 | -32.63% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $53.29 | +87.65% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $5.45 | +248.62% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $69.15 | +41.72% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $22.51
Upside: +122.12%
Tourmaline Bio
Sep 15, 2025
Downgrades: Market Perform
Price Target: $35 → $48
Current: $47.90
Upside: +0.21%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $481.67
Upside: -2.42%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $73.09
Upside: -4.23%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $2.45
Upside: +63.27%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.71
Upside: +115.63%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $47.89
Upside: +50.34%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $16.38
Upside: +205.25%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.50
Upside: +284.62%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $24.75
Upside: +102.02%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $6.90
Upside: +392.75%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $23.02
Upside: +52.04%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $3.05
Upside: +457.38%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $9.84
Upside: +306.50%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $31.96
Upside: +181.60%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $42.15
Upside: +184.70%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $25.98
Upside: +119.40%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $54.92
Upside: -32.63%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $53.29
Upside: +87.65%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $5.45
Upside: +248.62%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $69.15
Upside: +41.72%